Hansa Biopharma announces first patient treated in the post-authorization efficacy study (PAES) of Idefirix® (imlifidase) in highly sensitized kidney transplant patients

/PRNewswire/ -- Hansa Biopharma AB, "Hansa" (Nasdaq Stockholm: HNSA), pioneer in enzyme technology for rare immunological conditions, announces today that the...

Related Keywords

Sweden ,Stockholm ,Spain ,Jordan ,Barcelona ,Comunidad Autonoma De Cataluna ,Hansa Biopharma ,Vincenza Nigro ,Klaus Sindahl ,Oriol Bestard ,Katja Margell ,Christian Kjellman ,European Union ,Hebron University Hospital ,European Medicines Agency ,European Medicines Agency Ema Priority ,Head Of Corporate Communications ,Nasdaq Stockholm ,Kidney Transplantation ,Chief Scientific Officer ,Kidney Transplant Franchise Lead ,Human Leukocyte Antigens ,European Marketing Authorization ,End Stage Renal Disease ,Product Characteristics ,European Medicines ,Englj Med ,